Home List your patent My account Help Support us
Clincally-Verified (@UPenn) Pharmaceutical for Triglycerides
[Category : - HEALTH]
[Viewed 768 times]
The underlying US Patent technology has been clinically verified by the University of Pennsylvania Cardiology Department.
Purchase of the patent Includes the highly relevant and sought-after domain: Link
Revolutionize overall blood lipid treatment with this groundbreaking pharmaceutical composition, patented under US Patent 7,879,375. This unique formula expertly combines sylibum marianum with either niacin, policosanol, or both, offering a versatile approach to managing cholesterol levels. This composition is proven effective in reducing total and LDL cholesterol while boosting HDL cholesterol, catering to a broad spectrum of human and animal health needs.
Clinical Trial Summary (U.Penn) and raw datarnLink
Key Highlights:
* Alters the oxidative metabolic pathway for niacin or niacin-related compounds to significantly enhance bio availability and efficacy vs. the leading prescription alternatives.
* Versatile Composition: Incorporates sylibum marianum with niacin and/or policosanol.
* Standardized Ingredients: sylibum marianum standardized up to 95% silymarin.rn3. Flexible Dosage: Doses range from 0.05 g/day to 10 g/day for milk thistle, 0.1 g/day to 30 g/day for niacin, and 0.5 mg/day to 5000 mg/day for policosanol.
Multiple Forms: Available in capsules, tablets, liquids, and more. Patent-Protected: US Patent 7,879,375, issued February 1, 2011.
Financial information
Desired outcome = sale of US Patent 7879375 along with highly-valuable domain: Link Product is currently active, and a good opportunity for a new owner with a wide distribution network and marketing engine to compete broadly at a national scale.
The product NIALOR utilizes the underlying patent and has been in mass production for over 15 years with no safety issues.
Valuation Reference Metrics
• Hypertriglyceridemia market size of ~ $10B in 2022
• Medium Chain Triglycerides market size of ~ $1B in 2022
• Slo-Niacin is the best comparable dietary supplement
a. Annual Revenue of >$5 million
b. No special IP other than unique slow-release tablet technology
c. Sold by Upsher-Smith to MainPointe/Magna Pharmaceuticals in 2017
• NIASPAN is the FDA-approved drug (very similar to Slo-Niacin)
a. Under patent protection until 2012, where it generated $911 million revenue
b. After patent protection (2015), revenue dropped to $76 million
• Lovaza (prescription fish oil) to treat hypertriglyceridemia – generated $117M (2015) revenue after going off-patent in 2013
Patent publications:
US 7879375
Asking price:
Make an offer
Make an offer
Great invention[ Home | List a patent | Manage your account | F.A.Q.|Terms of use | Contact us]
Copyright PatentAuction.com 2004-2017
Page created at 2025-04-05 7:53:38, Patent Auction Time.